Yaneisi Vázquez
A5020497070- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- COVID-19 Impact on Reproduction
- Viral gastroenteritis research and epidemiology
- vaccines and immunoinformatics approaches
Millennium Institute on Immunology and Immunotherapy
2021-2023
Pontificia Universidad Católica de Chile
2021-2023
The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. rapid development of safe protective vaccines against this disease is global priority. CoronaVac vaccine prototype based on inactivated SARS-CoV-2, which shown promising safety immunogenicity profiles in pre-clinical studies phase 1/2 trials China. To day, four 3 clinical are Brazil, Indonesia, Turkey, Chile. This article reports the results obtained subgroup participants...
We sought to identify potential antigens for discerning between humoral responses elicited after vaccination with CoronaVac (a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] inactivated vaccine), natural infection, or breakthrough infection.
Abstract Background Multiple vaccines against SARS-CoV-2 have been evaluated in clinical trials, but very few include the pediatric population. The inactivated vaccine CoronaVac ® has shown to be safe and immunogenic a phase 1/2 trial cohort China. This study is an interim safety immunogenicity report of 3 for healthy children adolescents Chile. Methods Participants aged 17 years old received two doses four-week interval. Local systemic adverse reactions were registered 699 participants that...
Abstract Background CoronaVac ® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- four-weeks after two doses , but are reduced at six to eight months doses. Here we report effect a booster dose on anti-SARS-CoV-2 immune response generated against variants concern (VOC) Delta Omicron in adults participating phase 3 clinical trial Chile. Methods Volunteers immunized...
Summary The SARS-CoV-2 Omicron variant has challenged the control of COVID-19 pandemic even in highly vaccinated countries. While a second booster mRNA vaccines improved immunity against SARS-CoV-2, humoral and cellular responses induced by an inactivated vaccine have not been studied. In context phase 3 clinical study, we report that CoronaVac ® increased neutralizing response ancestral virus yet showed poor neutralization variant. Additionally, isolated PBMCs displayed equivalent...
ABSTRACT Analytical methods for the differential determination between natural infection with SARS- CoV-2 vs. immunity elicited by vaccination or after immunization (breakthrough cases) represent attractive new research venues in context of ongoing COVID-19 pandemic caused Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Herein, we set out to compare humoral responses against several SARS-CoV-2 structural and non-structural proteins infected unvaccinated (convalescent),...